UMR INSERM 1308 CAPTuR, Faculty of Medicine, University of Limoges, Limoges, France.
Carcidiag Biotechnologies company, Guéret, France.
Br J Cancer. 2024 Nov;131(9):1425-1436. doi: 10.1038/s41416-024-02839-9. Epub 2024 Sep 20.
Despite advances in diagnosis and treatment in lung cancer, therapies still fail to improve patient management due to resistance mechanisms and relapses. As Cancer stem cells (CSCs) directly contribute to tumor growth and therapeutic resistance, their clinical detection represents a major challenge. However specific and additional CSC markers lack. Thus, our aim was to achieve selective detection of CSCs with specific glycan patterns and assess the CSCs burden to predict the risk of relapse in NSCLC tumors.
The lung CSCs detection and sorting with a lectin MIX were assessed and compared to CD133 in vitro. Then, its putative role as CSC biomarker was evaluated in vivo and its clinical significance on 221 NSCLC patients.
We showed a significant CSCs enrichment in the MIX+ sorted fraction compared to CD133+ cells and confirmed its high tumorigenic capacity. The MIX prognostic value on the overall survival from early stages patients was validated suggesting its potential for detecting CSCs directly linked to tumor aggressiveness.
The MIX could be more relevant for detecting and sorting CSCs than CD133. Moreover, its prognosis value could enable clinicians to better classify early-stage patients at high risk of relapse in order to tailor therapeutic decisions.
尽管在肺癌的诊断和治疗方面取得了进展，但由于耐药机制和复发，治疗仍未能改善患者的管理。由于癌症干细胞（CSC）直接促进肿瘤生长和治疗耐药性，因此其临床检测是一个重大挑战。然而，缺乏特定和额外的 CSC 标志物。因此，我们的目的是利用特定的聚糖模式选择性检测 CSC，并评估 CSC 负担，以预测 NSCLC 肿瘤的复发风险。
评估了用凝集素 MIX 进行肺 CSC 的检测和分选，并与体外 CD133 进行了比较。然后，在体内评估了其作为 CSC 生物标志物的潜在作用，并在 221 名 NSCLC 患者中评估了其临床意义。
与 CD133+细胞相比，MIX+分选部分显著富集了 CSC，证实了其高致瘤能力。MIX 对早期患者总生存期的预后价值得到了验证，这表明其具有直接检测与肿瘤侵袭性相关的 CSC 的潜力。
与 CD133 相比，MIX 可能更适合用于检测和分选 CSC。此外，其预后价值可以使临床医生更好地对高复发风险的早期患者进行分类，以便制定治疗决策。
